Additional details are expected later Wednesday.
Gilead Sciences, Inc. said Wednesday it was “aware of positive data” from a federal trial of the experimental drug remdesivir in treating COVID-19 patients, resulting in a trading halt for Gilead’s stock—and further details are expected to be announced later in the day.
In a separate Wednesday press release, Gilead announced initial results from its own remdesivir study on giving patients five days of the drug versus 10 days of the drug, and found outcomes were about the same.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gilead says early results of coronavirus drug trial show improvement with shorter remdesivir treatmentGilead says preliminary results of a coronavirus drug trial showed at least 50% of patients treated with a 5-day dosage of remdesivir improved, and more than half were discharged from the hospital within 2 weeks.
Read more »
Gilead reports 'positive data' on remdesivir coronavirus drug trial
Read more »
Coronavirus treatment: Gilead says positive data on remdesivir coming - Business InsiderOne of the most promising coronavirus treatment candidates succeeded in a late-stage trial in COVID-19 patients, Gilead said Wednesday.
Read more »
Gilead Sciences says there are 'positive data' from a study on possible Covid-19 treatment remdesivirThere's 'positive data' emerging from a study on possible Covid-19 treatment remdesivir, the maker of the investigational drug says
Read more »
What to watch today: Dow set to jump on positive data on possible Gilead coronavirus treatmentDow futures soar on positive data about a possible Gilead Sciences coronavirus treatment.
Read more »
Stocks Rally, Dow Up 400 Points After Gilead Treatment Shows ‘Positive Data’The market got a boost from news of a potential treatment for coronavirus.
Read more »